A brief overview of the national outbreak of e-cigarette, or vaping, product use ─associated lung injury (EVALI) and the primary causes
Autor
Kiernan, Emily
Click, Eleanor S.
Melstrom, Paul
Evans, Mary E.
Layer, Mark R.
Weissman, David N.
Reagan-Steiner, Sarah
Wiltz, Jennifer L.
Hocevar, Susan
Goodman, Alyson B.
Twentyman, Evelyn
Institución
Resumen
For the purpose of public health surveillance, cases are defined by a history of e-cigarette, or vaping, use within
90 days prior to symptom onset, pulmonary infiltrates on chest imaging, and the absence of infectious or other
alternative diagnoses. [2] EVALI cases were first reported to CDC in August 2019. National emergency
department data and active case reporting from state health departments around the country show a sharp rise in
symptoms or cases of EVALI in June 2019, a peak in September 2019, and a gradual, but persistent decline
since then. Although cases related to the outbreak have decreased, new cases continued to be reported to CDC
by state health departments and samples connected to EVALI patients continued to be tested by both CDC and
FDA through February 2020 when systematic reporting to CDC ceased because of the decline in the epidemic.
[4-6] However, some states have continued to identify cases and clinicians should remain vigilant in identifying
and treating patients who may have EVALI. [7]